# EMOVI

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/emovi

- Industry: Medical Devices & Equipment
- Headquarters: Laval, Canada
- Website: www.emovi.ca
- Total disclosed funding: $11M
- Latest round: Series C (Mar 4, 2019)
- Investors on record: 3

## About

EMOVI, Inc. is a healthcare innovation company that develops advanced medical devices, specifically the KneeKG® System, to enhance knee function assessment and treatment decisions for healthcare professionals.Founded in 2007, EMOVI, Inc. is headquartered in Laval, Canada. The company specializes in the KneeKG® System, an innovative tool for measuring dynamic knee alignment. In March 2019, EMOVI secured CAD 15 million during its Series C funding round led by TVM Capital Life Science, with participation from Desjardins Capital and StandUp Ventures. This funding marks a pivotal step towards expanding their technological advancements and market reach. The company has completed one notable funding deal to date.Emovi, a healthcare innovation company headquartered in Laval, Quebec, specializes in the development of the KneeKG® System, an advanced medical device designed to accurately measure the 3D dynamic alignment of the knee. This system leverages artificial intelligence to provide healthcare professionals with objective data that aids in decision-making for knee alignment correction and restoration of knee function. The Knee Kinesiography exam, facilitated by the KneeKG System, allows for immediate results in various clinical settings, including doctor’s offices, rehabilitation centers, and sports performance clinics. Emovi's customer base includes orthopedic surgeons, rehabilitation specialists, and sports medicine practitioners, primarily serving healthcare markets across North America and Europe. The KneeKG System is the first approved Class II device of its kind, having received FDA 510(k) clearance, Health Canada licensing, and CE marking.Emovi generates revenue through the sale of its KneeKG® System and related services to healthcare providers. Transactions typically occur on a B2B basis, where clinics and hospitals purchase the KneeKG devices directly from the company, along with potential training and support services. The structure of these transactions may include one-time equipment purchases, along with ongoing service agreements for software updates and maintenance. While specific pricing information is not disclosed, the company focuses on delivering value through its innovative technology, which aims to enhance clinical outcomes and streamline patient workflows. The integration of the KneeKG System into medical practices not only drives revenue for Emovi but also supports healthcare providers in offering improved patient care.In March 2019, EMOVI, Inc. raised CAD 15 million in Series C funding, led by TVM Capital Life Science, to support the development of new products and expansion into new markets. The company is focused on enhancing the KneeKG® System, with plans to introduce additional functionalities that align with healthcare provider needs. EMOVI aims to expand its market presence in Europe and the United States by 2023, leveraging this funding to drive strategic marketing initiatives and support product development efforts.

## Funding rounds

- Series C, Mar 4, 2019, $11M — TVM Capital Life Science, Desjardins Capital, StandUp Ventures

## Investors

- TVM Capital Life Science (https://capitalatlas.ai/funds/tvm-capital-life-science) — Series C
- Desjardins Capital (https://capitalatlas.ai/funds/desjardins-capital) — Series C
- StandUp Ventures (https://capitalatlas.ai/funds/standup-ventures) — Series C